This document provides safety information for a mixture called CIPC 300 g/L HN. It contains the following key details:
- The product is a mixture used as a plant growth regulator in agriculture.
- Prolonged or repeated exposure may cause damage to organs and is suspected of causing cancer. It can cause eye, skin and respiratory irritation and an allergic skin reaction.
- Precautions include obtaining special instructions before use, wearing protective equipment, and seeking medical advice if exposed, feeling unwell or experiencing skin or eye irritation. The product is toxic to aquatic life with long lasting effects.
The document provides information about the European Medicines Agency (EMA) and marketing authorization procedures in the European Union. It describes the EMA's role in evaluating and authorizing medicines, its committees and membership. Four procedures for marketing authorization are outlined: centralized, national, mutual recognition and decentralized. The centralized procedure allows marketing across the EU, while national and decentralized are for individual countries. Mutual recognition relies on an existing national authorization. Timelines for evaluation are included.
The pharmaceutical industry in Serbia contributes 0.7% to GDP and employs around 7,000 people. In 2011, the industry's gross production was over 450 million Euros. Domestic producers supply around 75% of medicines in Serbia by number of boxes sold, accounting for 45% of cash flow. While imports of medicines have been growing, exports have also increased, reaching 208.3 million dollars in 2011. The industry presents opportunities for growth through further privatization of domestic companies and EU integration.
The document discusses various schedules under the Drugs and Cosmetics Act of India. It provides details on Schedule H, J, W, X, and Y which are important for prescribers. Schedule H contains a list of prescription-only drugs that can only be sold by a registered medical practitioner. Schedules J, W, X also restrict drugs in some way. The document gives an overview of the various schedules and focuses on Schedule H, providing a list of over 500 drugs that are included in this schedule.
Granted Pharmaceutical Patent Applications in India by Indian Patent Office. 1001 drug patents granted by Patent Office in India between April 2010 and March 2013, of which 771 were granted to foreign drug makers.
This document establishes new regulations for the registration of biological medicinal products in Argentina. It defines biological products and outlines specific requirements and procedures for their registration, including information that must be included in registration certificates. Evaluation and approval of registration applications will ensure biological products have favorable benefit-risk ratios, sufficient therapeutic efficacy, adequate quality and composition supported by application materials.
This document outlines general and special labeling requirements for drugs and cosmetics under the Drugs & Cosmetics Act of 1940 and its Rules of 1945 in India. It provides details on what information must be included on labels, such as the drug name, ingredients, manufacturer information, batch details, and expiry date. It also specifies additional labeling for certain drug schedules, like Schedule H which requires a prescription, as well as for external preparations, ophthalmic products, and veterinary medicines. Sample labels are given for various drug schedules and uses. The document also lists permitted colors that can be used in drugs.
The document outlines the Medical Devices Rules 2015 introduced by the Drug Regulatory Authority of Pakistan. Some key points:
- The rules were introduced to regulate over 1 million medical devices in Pakistan and protect public health by ensuring safety and effectiveness.
- A Medical Devices Board (MDB) is established as the regulatory authority responsible for registration of devices and conformity assessment bodies, issuing licenses, and enforcing implementation of the rules.
- The rules cover various aspects of medical devices including classification, registration, import/export, labeling, usage and advertising. Formats and a fee chart for various regulatory activities are also provided.
The document discusses quality assurance and regulatory control in the pharmaceutical industry. It describes key aspects of quality assurance including regulatory drug analysis and interpretation of data. Regulatory authorities like the FDA and DDA in Nepal establish rules and regulations to ensure safety, efficacy and quality of drugs. The FDA oversees drug approval and manufacturing inspections through centers like CDER. It also works with other agencies on issues like advertising claims (FTC), environmental protection (EPA), and workplace safety (OSHA). Similarly, Nepal's DDA regulates drug production, import/export, storage and consumption to implement the objectives of the Drug Act 2035.
The document provides information about the European Medicines Agency (EMA) and marketing authorization procedures in the European Union. It describes the EMA's role in evaluating and authorizing medicines, its committees and membership. Four procedures for marketing authorization are outlined: centralized, national, mutual recognition and decentralized. The centralized procedure allows marketing across the EU, while national and decentralized are for individual countries. Mutual recognition relies on an existing national authorization. Timelines for evaluation are included.
The pharmaceutical industry in Serbia contributes 0.7% to GDP and employs around 7,000 people. In 2011, the industry's gross production was over 450 million Euros. Domestic producers supply around 75% of medicines in Serbia by number of boxes sold, accounting for 45% of cash flow. While imports of medicines have been growing, exports have also increased, reaching 208.3 million dollars in 2011. The industry presents opportunities for growth through further privatization of domestic companies and EU integration.
The document discusses various schedules under the Drugs and Cosmetics Act of India. It provides details on Schedule H, J, W, X, and Y which are important for prescribers. Schedule H contains a list of prescription-only drugs that can only be sold by a registered medical practitioner. Schedules J, W, X also restrict drugs in some way. The document gives an overview of the various schedules and focuses on Schedule H, providing a list of over 500 drugs that are included in this schedule.
Granted Pharmaceutical Patent Applications in India by Indian Patent Office. 1001 drug patents granted by Patent Office in India between April 2010 and March 2013, of which 771 were granted to foreign drug makers.
This document establishes new regulations for the registration of biological medicinal products in Argentina. It defines biological products and outlines specific requirements and procedures for their registration, including information that must be included in registration certificates. Evaluation and approval of registration applications will ensure biological products have favorable benefit-risk ratios, sufficient therapeutic efficacy, adequate quality and composition supported by application materials.
This document outlines general and special labeling requirements for drugs and cosmetics under the Drugs & Cosmetics Act of 1940 and its Rules of 1945 in India. It provides details on what information must be included on labels, such as the drug name, ingredients, manufacturer information, batch details, and expiry date. It also specifies additional labeling for certain drug schedules, like Schedule H which requires a prescription, as well as for external preparations, ophthalmic products, and veterinary medicines. Sample labels are given for various drug schedules and uses. The document also lists permitted colors that can be used in drugs.
The document outlines the Medical Devices Rules 2015 introduced by the Drug Regulatory Authority of Pakistan. Some key points:
- The rules were introduced to regulate over 1 million medical devices in Pakistan and protect public health by ensuring safety and effectiveness.
- A Medical Devices Board (MDB) is established as the regulatory authority responsible for registration of devices and conformity assessment bodies, issuing licenses, and enforcing implementation of the rules.
- The rules cover various aspects of medical devices including classification, registration, import/export, labeling, usage and advertising. Formats and a fee chart for various regulatory activities are also provided.
The document discusses quality assurance and regulatory control in the pharmaceutical industry. It describes key aspects of quality assurance including regulatory drug analysis and interpretation of data. Regulatory authorities like the FDA and DDA in Nepal establish rules and regulations to ensure safety, efficacy and quality of drugs. The FDA oversees drug approval and manufacturing inspections through centers like CDER. It also works with other agencies on issues like advertising claims (FTC), environmental protection (EPA), and workplace safety (OSHA). Similarly, Nepal's DDA regulates drug production, import/export, storage and consumption to implement the objectives of the Drug Act 2035.
This presentation consists of detailed rules and regulations related to the sales of drugs under the Drugs & Cosmetics Act. This covers the requirements for wholesale, retail, and restricted licenses.
The document provides an overview of the Drugs and Cosmetics Act of 1940 in India. Some key points:
1) The Act was established to regulate the manufacture, sale, and import of drugs and cosmetics in order to ensure quality and safety. It covers definitions, licensing, inspections, and penalties for violations.
2) Administration involves advisory boards, analytical testing labs, and licensing authorities at central and state levels. The Drugs Technical Advisory Board advises the government on technical issues.
3) Manufacturing, sale, and import of drugs require licenses that mandate compliance with good practices, record keeping, and product standards. Violations can result in imprisonment and fines.
HIGHLIGHTED: Guidance for Industry: Fulfilling Regulatory Requirements for Po...NextWorks
This is the highlighted version of FDA's Guidance for Industry
Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics from January 2014.
When these guidances come out, I typically go through them and highlight the most relevant portions for those who need to skim through or refresh their memory.
This document summarizes amendments made to Administrative Order 56 s. 1989 regarding rules and regulations on licensing drug establishments and other authorizations in the Philippines. The amendments were made to align drug establishment licensing with recently passed laws, streamline regulatory processes, and promote electronic transactions. Key changes include expanding the scope to various entities involved with pharmaceutical products, defining important terms, and requiring licenses or permits for various activities involving pharmaceuticals.
HIGHLIGHTED: Guidance for Industry: Internet/Social Media Platforms: Correcti...NextWorks
This is the highlighted version of FDA's Guidance for Industry
Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices
When these guidances come out, I typically go through them and highlight the most relevant portions for those who need to skim through or refresh their memory.
This document is an act passed in 2006 to establish the Food Safety and Standards Authority of India (FSSAI). [1] It consolidates various food laws and establishes standards for food articles. [2] FSSAI will be responsible for laying down science-based standards for food and regulating manufacturing, storage, distribution and import of food. [3] The act contains provisions for food safety, licensing, enforcement, offences and penalties.
Drug labeling in India is regulated by the Drugs and Cosmetics Rules 1945. All drug labels must conform to these specifications and include information like the drug name, quantity, active ingredients, manufacturer details, batch number, expiration date and storage conditions. Prescription drug labels have additional requirements depending on the drug schedule. Package inserts provide directions for safe use to healthcare professionals. Proper drug labeling is important for the safe use of medicines.
This document provides information about a welcome address given by Dr. B. L. Meena, Director General of Drugs Control Administration in Andhra Pradesh, to foreign regulatory delegates attending BioAsia-2013. It discusses the roles and functions of the Central Drugs Standard Control Organization and the Andhra Pradesh Drugs Control Administration in regulating drugs and cosmetics. It also provides details about the licensing process, GMP compliance, inspection and enforcement activities carried out to ensure quality and safety of drugs in India.
The document outlines the various agencies involved in ensuring food quality and safety in India. The Prevention of Food Adulteration Act 1954 is legislated by the Ministry of Health and Family Welfare and implemented by state governments. The Central Committee on Food Standards advises the central and state governments on food standards. Food inspectors play a key role by collecting food samples for testing and enforcing licensing requirements. Other agencies involved include the Bureau of Indian Standards, Agricultural Produce Marketing Committees, and various ministries that oversee other food-related legislation.
Country study: Availability of essential medicines Arete-Zoe, LLC
The document analyzes the availability of essential medicines in the Czech Republic as compared to the WHO Model List of Essential Medicines. It finds that while many essential medicines are available locally, some important ones are still unavailable. It provides breakdowns by organ class of medicines available and unavailable. Key medicines reported as unavailable include hyoscine hydrobromide, oral rehydration salts, and magnesium sulfate.
This document provides an overview of the administration of the Drugs and Cosmetics Act and Rules in India. It discusses the roles of various analytical, executive, and advisory bodies involved in drug regulation. It also outlines the qualifications, duties, and powers of key regulatory positions like Government Analysts, Drugs Inspectors, and the procedures they follow to inspect facilities, collect samples, test drugs, and take action if drugs are found to be substandard.
The document discusses herbal drug regulation in India. It provides an overview of the types of herbal formulations regulated in India, the advantages of herbal drugs, market statistics, and the various schedules and rules that govern herbal drugs under the Drugs and Cosmetics Act. It also discusses Ayush regulations for herbal drugs, requirements for clinical trials, and issues related to promoting herbal drugs in India. The future prospects section outlines opportunities to improve regulation and development of the herbal drug industry in India.
This document contains the answers to an assignment given to pharmacy students at an institute in India. It includes answers to 20 multiple choice questions about the Drug and Cosmetic Act and Rules as well as the Narcotic Drugs and Psychotropic Substances Act. It also provides detailed answers to 5 additional questions about the constitution of the Drugs Technical Advisory Board, prohibited drug advertisements, offenses and penalties under the NDPS Act, and the procedure an inspector follows for taking drug samples for analysis.
Evira acts as Finland's central competent authority for food export issues. It is responsible for cooperation with third country officials on food safety and animal disease, providing declarations of compliance on Finland's food safety controls and exporting facilities. Evira also handles market access questionnaires, inspections and audits to verify exporter compliance, and administration of veterinary and phytosanitary certificates. Export requirements vary depending on the product and destination country, with animal products generally having more stringent rules. Evira provides support to help Finnish SMEs navigate export regulations and requirements.
The availability of Essential Medicines in Hungary shows summary tables that compare the World Health Organization Essential Medicines List (WHO EML) with the National Substitution List (NL) by system organ class. The graphs are color-coded for more natural orientation: WHO EML products are marked blue, NL products are green, and products included in both lists are yellow. Many registrations include the number of individual drug forms, including package sizes and dosage forms, rather than a single registration number. This is because different dosage forms may have different indications. Drugs are categorized by ATC Code; that means some active ingredients are listed in all relevant forms and system organ classes. The dataset is presented as a summary and then in detail by organ class and ATC subclass as relevant/appropriate. The focus of the following analysis is on essential medicines that are not available in Hungary, and evaluation of the situation in the context of public health needs and global drug shortages. To this end, the Essential List of Medicines defined by the World Health Organization (WHO) is compared to the Substitution List, which can be found on the website of The National Institute of Pharmacy and Nutrition.
The document discusses the National Pharmaceutical Pricing Authority (NPPA) and the Drug Price Control Order (DPCO) in India. Some key points:
- NPPA was established to fix and revise prices of essential medicines and ensure their availability. DPCO enables the government to regulate prices of essential medicines.
- DPCO lists essential medicines and regulates their ceiling prices based on market data. It aims to make medicines affordable while ensuring quality and rational use.
- Exemptions are provided for new patented drugs developed locally through R&D for 5 years to encourage innovation. DPCO 2019 also exempts orphan drugs to encourage their production.
The document lists updates made to images of a bed and various areas of a facility including a DJ booth, lounge, and multiple toilets identified for males and females. It also outlines design revisions made to the bed and other areas to reduce costs, such as less glazing on facades and toilets, changing materials, and using a different vinyl brand, resulting in total savings of over 1 million Philippine pesos.
Khaled Hosseini is an Afghan-American author known for his bestselling novels The Kite Runner, A Thousand Splendid Suns, and And the Mountains Echoed. The document provides background on Hosseini and an overview of his novel A Thousand Splendid Suns, including its setting in Afghanistan, characters such as Mariam and Laila, themes of war and gender inequality, and literary devices used.
This document appears to be a leaflet or instruction manual for a product called Cyperkill as it contains page numbers and references to creating a CYPERKILL LEAFLET, though no other text or images are provided. It includes at least 8 pages as pages 1 through 8 are referenced. The date associated is March 24, 2016.
This presentation consists of detailed rules and regulations related to the sales of drugs under the Drugs & Cosmetics Act. This covers the requirements for wholesale, retail, and restricted licenses.
The document provides an overview of the Drugs and Cosmetics Act of 1940 in India. Some key points:
1) The Act was established to regulate the manufacture, sale, and import of drugs and cosmetics in order to ensure quality and safety. It covers definitions, licensing, inspections, and penalties for violations.
2) Administration involves advisory boards, analytical testing labs, and licensing authorities at central and state levels. The Drugs Technical Advisory Board advises the government on technical issues.
3) Manufacturing, sale, and import of drugs require licenses that mandate compliance with good practices, record keeping, and product standards. Violations can result in imprisonment and fines.
HIGHLIGHTED: Guidance for Industry: Fulfilling Regulatory Requirements for Po...NextWorks
This is the highlighted version of FDA's Guidance for Industry
Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics from January 2014.
When these guidances come out, I typically go through them and highlight the most relevant portions for those who need to skim through or refresh their memory.
This document summarizes amendments made to Administrative Order 56 s. 1989 regarding rules and regulations on licensing drug establishments and other authorizations in the Philippines. The amendments were made to align drug establishment licensing with recently passed laws, streamline regulatory processes, and promote electronic transactions. Key changes include expanding the scope to various entities involved with pharmaceutical products, defining important terms, and requiring licenses or permits for various activities involving pharmaceuticals.
HIGHLIGHTED: Guidance for Industry: Internet/Social Media Platforms: Correcti...NextWorks
This is the highlighted version of FDA's Guidance for Industry
Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices
When these guidances come out, I typically go through them and highlight the most relevant portions for those who need to skim through or refresh their memory.
This document is an act passed in 2006 to establish the Food Safety and Standards Authority of India (FSSAI). [1] It consolidates various food laws and establishes standards for food articles. [2] FSSAI will be responsible for laying down science-based standards for food and regulating manufacturing, storage, distribution and import of food. [3] The act contains provisions for food safety, licensing, enforcement, offences and penalties.
Drug labeling in India is regulated by the Drugs and Cosmetics Rules 1945. All drug labels must conform to these specifications and include information like the drug name, quantity, active ingredients, manufacturer details, batch number, expiration date and storage conditions. Prescription drug labels have additional requirements depending on the drug schedule. Package inserts provide directions for safe use to healthcare professionals. Proper drug labeling is important for the safe use of medicines.
This document provides information about a welcome address given by Dr. B. L. Meena, Director General of Drugs Control Administration in Andhra Pradesh, to foreign regulatory delegates attending BioAsia-2013. It discusses the roles and functions of the Central Drugs Standard Control Organization and the Andhra Pradesh Drugs Control Administration in regulating drugs and cosmetics. It also provides details about the licensing process, GMP compliance, inspection and enforcement activities carried out to ensure quality and safety of drugs in India.
The document outlines the various agencies involved in ensuring food quality and safety in India. The Prevention of Food Adulteration Act 1954 is legislated by the Ministry of Health and Family Welfare and implemented by state governments. The Central Committee on Food Standards advises the central and state governments on food standards. Food inspectors play a key role by collecting food samples for testing and enforcing licensing requirements. Other agencies involved include the Bureau of Indian Standards, Agricultural Produce Marketing Committees, and various ministries that oversee other food-related legislation.
Country study: Availability of essential medicines Arete-Zoe, LLC
The document analyzes the availability of essential medicines in the Czech Republic as compared to the WHO Model List of Essential Medicines. It finds that while many essential medicines are available locally, some important ones are still unavailable. It provides breakdowns by organ class of medicines available and unavailable. Key medicines reported as unavailable include hyoscine hydrobromide, oral rehydration salts, and magnesium sulfate.
This document provides an overview of the administration of the Drugs and Cosmetics Act and Rules in India. It discusses the roles of various analytical, executive, and advisory bodies involved in drug regulation. It also outlines the qualifications, duties, and powers of key regulatory positions like Government Analysts, Drugs Inspectors, and the procedures they follow to inspect facilities, collect samples, test drugs, and take action if drugs are found to be substandard.
The document discusses herbal drug regulation in India. It provides an overview of the types of herbal formulations regulated in India, the advantages of herbal drugs, market statistics, and the various schedules and rules that govern herbal drugs under the Drugs and Cosmetics Act. It also discusses Ayush regulations for herbal drugs, requirements for clinical trials, and issues related to promoting herbal drugs in India. The future prospects section outlines opportunities to improve regulation and development of the herbal drug industry in India.
This document contains the answers to an assignment given to pharmacy students at an institute in India. It includes answers to 20 multiple choice questions about the Drug and Cosmetic Act and Rules as well as the Narcotic Drugs and Psychotropic Substances Act. It also provides detailed answers to 5 additional questions about the constitution of the Drugs Technical Advisory Board, prohibited drug advertisements, offenses and penalties under the NDPS Act, and the procedure an inspector follows for taking drug samples for analysis.
Evira acts as Finland's central competent authority for food export issues. It is responsible for cooperation with third country officials on food safety and animal disease, providing declarations of compliance on Finland's food safety controls and exporting facilities. Evira also handles market access questionnaires, inspections and audits to verify exporter compliance, and administration of veterinary and phytosanitary certificates. Export requirements vary depending on the product and destination country, with animal products generally having more stringent rules. Evira provides support to help Finnish SMEs navigate export regulations and requirements.
The availability of Essential Medicines in Hungary shows summary tables that compare the World Health Organization Essential Medicines List (WHO EML) with the National Substitution List (NL) by system organ class. The graphs are color-coded for more natural orientation: WHO EML products are marked blue, NL products are green, and products included in both lists are yellow. Many registrations include the number of individual drug forms, including package sizes and dosage forms, rather than a single registration number. This is because different dosage forms may have different indications. Drugs are categorized by ATC Code; that means some active ingredients are listed in all relevant forms and system organ classes. The dataset is presented as a summary and then in detail by organ class and ATC subclass as relevant/appropriate. The focus of the following analysis is on essential medicines that are not available in Hungary, and evaluation of the situation in the context of public health needs and global drug shortages. To this end, the Essential List of Medicines defined by the World Health Organization (WHO) is compared to the Substitution List, which can be found on the website of The National Institute of Pharmacy and Nutrition.
The document discusses the National Pharmaceutical Pricing Authority (NPPA) and the Drug Price Control Order (DPCO) in India. Some key points:
- NPPA was established to fix and revise prices of essential medicines and ensure their availability. DPCO enables the government to regulate prices of essential medicines.
- DPCO lists essential medicines and regulates their ceiling prices based on market data. It aims to make medicines affordable while ensuring quality and rational use.
- Exemptions are provided for new patented drugs developed locally through R&D for 5 years to encourage innovation. DPCO 2019 also exempts orphan drugs to encourage their production.
The document lists updates made to images of a bed and various areas of a facility including a DJ booth, lounge, and multiple toilets identified for males and females. It also outlines design revisions made to the bed and other areas to reduce costs, such as less glazing on facades and toilets, changing materials, and using a different vinyl brand, resulting in total savings of over 1 million Philippine pesos.
Khaled Hosseini is an Afghan-American author known for his bestselling novels The Kite Runner, A Thousand Splendid Suns, and And the Mountains Echoed. The document provides background on Hosseini and an overview of his novel A Thousand Splendid Suns, including its setting in Afghanistan, characters such as Mariam and Laila, themes of war and gender inequality, and literary devices used.
This document appears to be a leaflet or instruction manual for a product called Cyperkill as it contains page numbers and references to creating a CYPERKILL LEAFLET, though no other text or images are provided. It includes at least 8 pages as pages 1 through 8 are referenced. The date associated is March 24, 2016.
This safety data sheet provides information on a herbicide product called ALIACINE 400 EC. It contains the active ingredient chlorpropham, as well as solvent naphtha and calcium salts. The document lists the product identifiers, relevant uses and advised against uses. It identifies the supplier and provides emergency contact information. Hazard information is presented, including classifications like skin and eye irritation, sensitization, carcinogenicity and hazards to the aquatic environment. Precautionary statements and handling advice are included.
This document provides a safety data sheet for Trinexis, which is a mixture used as a plant growth regulator in agriculture. It contains Trinexapac-ethyl (25%) and other ingredients. Section 1 identifies the product and supplier. Section 2 outlines the hazards, including that it may cause an allergic skin reaction and is toxic to aquatic life with long lasting effects. Section 3 lists the ingredients. Sections 4-7 provide first aid measures, firefighting guidance, accidental release measures, and advice for safe handling and storage. Section 8 covers exposure controls and personal protective equipment needed such as gloves and eye protection.
1. The document is a safety data sheet for the product Cythrin Max, which contains the active ingredient cypermethrin.
2. Cythrin Max is classified as flammable, acutely toxic if inhaled, causing skin and eye irritation. It may cause respiratory tract irritation, drowsiness or dizziness. Ingestion may be fatal. It is also very toxic to aquatic life with long lasting effects.
3. The sheet provides instructions for safe handling, storage, firefighting, accidental release measures, first aid, and composition/information on ingredients of the product. It identifies the product identifiers, hazards, composition, and supplier contact information.
This safety data sheet provides information on the product NeoNet L 500. It identifies the product, supplier contact information, product composition, hazards, first aid measures, firefighting measures, accidental release measures, handling and storage, exposure controls and personal protection, physical and chemical properties, stability and reactivity, toxicological information, and other information. The main hazardous components are identified as CIPC (47-51%) which is suspected of causing cancer and may cause damage to organs through prolonged or repeated exposure.
This safety data sheet provides information on the product KASKARA EW. It contains a mixture of herbicides including 2,4-D EHE, dicamba DMA salt, and triclopyr butoxy ethyl ester. The product is classified as harmful if swallowed, may cause an allergic skin reaction, and is very toxic to aquatic life with long lasting effects. Personal protective equipment including gloves and eye protection should be worn when handling. Spills should be cleaned up promptly and the product stored away from heat, sparks and flames.
This document provides a safety data sheet for the product TALISMA EC. It contains information on product identification, composition, hazards, first aid measures, accidental release measures, handling and storage, exposure controls and personal protection, physical and chemical properties, stability and reactivity, toxicological information, and other safety-related details. The main hazardous components are cypermethrin and piperonyl butoxide. TALISMA EC is harmful if swallowed, may cause an allergic skin reaction, and is very toxic to aquatic life with long lasting effects.
1. The document is a safety data sheet for the product Cythrin Max, which contains the active ingredient cypermethrin.
2. Cythrin Max is classified as flammable, acutely toxic if inhaled, causing skin and eye irritation. It may cause respiratory tract irritation, drowsiness or dizziness. Ingestion may be fatal. It is very toxic to aquatic life with long lasting effects.
3. The safety data sheet provides instructions for safe handling, storage, firefighting measures, accidental release measures, first aid, and emergency contact information.
This document provides safety information for the product Proxanil. It contains the following key information:
- Proxanil is a fungicide mixture containing propamocarb hydrochloride, cymoxanil, citric acid, and propylene glycol.
- It may be corrosive to metals and cause skin and eye irritation. It is suspected of damaging fertility and the unborn child.
- Personal protective equipment including gloves, goggles and protective clothing should be worn when handling.
- In case of accidental release, collect any spills and dispose of properly. Ventilate areas of spill and wash exposed skin.
- Store in original closed container away from heat and ignition sources. Keep
This document provides safety information for the product Forester. It identifies Forester as a mixture containing the active ingredient Cypermethrin cis/trans at a concentration of 9.6-10.6%. Forester is classified as harmful if swallowed, may cause an allergic skin reaction, and is very toxic to aquatic life with long lasting effects. Emergency contact information is provided. Personal protective equipment is advised when handling Forester, which should be stored in a cool, well ventilated area away from heat and direct sunlight.
1) The document provides safety information for the product SYLLIT 400 SC, including its identification, hazards, composition, and safety recommendations for handling and storage.
2) SYLLIT 400 SC is a fungicide containing 38-42% dodine as the main active ingredient and is toxic if inhaled.
3) The product requires protective equipment including gloves, goggles and respiratory protection during handling and first aid measures are described for accidental exposure.
This safety data sheet provides information on Balear 720 SC, a fungicide product containing the active ingredient chlorothalonil. It identifies the product and company details, lists the product classification according to EU regulations including serious eye damage and skin sensitization hazards. It provides guidance on first aid measures in case of exposure and instructions for safe handling and storage of the product.
This document provides safety information for the product ZOXIS. It identifies the product as a fungicide containing the active ingredient azoxystrobin. Key information includes:
- Hazards associated with the product include skin sensitization and being very toxic to aquatic life with long lasting effects.
- The product supplier details are provided.
- Personal protective equipment should be worn when handling the product.
- In the event of a spill, contaminated areas should be cleaned and the product collected for disposal.
- The product should be stored in a cool, well-ventilated place and kept away from ignition sources.
COVID-19 RT-PCR Ultra Sensitivity Kit Profile 202201.pdfFerdous Hasan
This document provides instructions for using the Novel Coronavirus (COVID-19) RT-PCR Kit for detecting SARS-CoV-2. The kit contains reagents for extracting viral RNA from patient samples and performing real-time PCR to detect ORF1ab, N, and/or E genes. The procedure involves extracting RNA from respiratory samples, preparing a master mix, adding samples and controls to PCR tubes, and running PCR with specified cycling conditions. Positive and negative controls are included to validate the results. Precautions are described to handle samples and reagents safely and avoid contamination.
This document provides safety information about Brodifacoum Technical Material. It lists Brodifacoum as the active ingredient and classifies it as highly toxic if swallowed or absorbed through skin contact. The document outlines handling, storage, exposure and first aid procedures to mitigate health and environmental risks. It also provides physical and chemical properties, toxicological data, and disposal guidance in compliance with relevant regulations.
This safety data sheet provides information on Pyrus 400 SC, a fungicide product. It contains the active ingredient pyrimethanil at a concentration of 35.5-38.5%. The product is toxic to aquatic life with long lasting effects and precautions should be taken to avoid release to the environment. Personal protective equipment including gloves and safety glasses are recommended when handling the product.
This document provides a safety data sheet for Proplant, a fungicide product. It identifies the product and supplier, lists its main uses as an agricultural fungicide, and classifies the product as a skin sensitizer. The document provides guidance on safe handling, storage, exposure controls and emergency procedures for the product. Key hazards are identified as skin sensitization and the need to avoid contact with skin and inhalation of the product.
This safety data sheet provides information on Genoxone ZX, a herbicide mixture containing triclopyr and 2,4-D. It is classified as flammable and hazardous to aquatic environments. The document lists the product identifiers, composition, hazards, first aid measures, firefighting guidance, accidental release measures, and handling and storage recommendations. Personal protective equipment including gloves, eye protection and protective clothing should be worn when handling the product.
Bromadiolone is a rodenticide used to formulate baits. It is classified as very toxic if swallowed or absorbed through skin. It causes internal bleeding and damage to organs over prolonged or repeated exposure. Bromadiolone is also very toxic to aquatic life and can pollute soil and water. Proper protective equipment should be worn when handling. It degrades slowly and can bioaccumulate in organisms. Disposal requires approved incineration or treatment due to its toxicity.
This safety data sheet provides information on the product SIGNAL. It contains hazards identification, composition/information on ingredients, first aid measures, and other important safety and handling information. The product is classified as harmful if swallowed, may cause respiratory irritation, and is very toxic to aquatic life with long lasting effects. It contains the active ingredient cypermethrin.
This safety data sheet provides information on the product TALISMA UL. It contains a mixture of cypermethrin and piperonyl butoxide. The document lists hazards such as being very toxic to aquatic life with long lasting effects. It provides handling, storage, exposure and personal protective equipment recommendations. The product has a density of 0.8933 g/ml and a flash point above 79°C. It is not readily biodegradable and components may bioaccumulate in fish and other organisms.
This document is a safety data sheet for Loctite 243 Threadlocker. It provides information on product identification, hazards, composition, first aid measures, firefighting measures, accidental release measures, handling and storage, exposure controls and personal protection, physical and chemical properties, stability and reactivity, toxicological information, ecological information, disposal considerations and regulatory information. The product contains several hazardous components that are classified for skin sensitization, aquatic toxicity, and other hazards. Personal protective equipment including gloves and proper ventilation are recommended when handling the product.
This document provides information on the identification, hazards, composition, and safe handling of calcium lignosulfonate. It identifies the substance and supplier, summarizes that it is not classified as hazardous but should be treated with caution. Exposure controls including protective equipment and storage requirements are outlined to safely handle the substance.
This document provides information on the identification, hazards, composition, and safe handling of calcium lignosulfonate. It identifies the substance, lists relevant hazards as low risk, and provides the contact information for the supplier, GREEN AGROCHEM, located in Beijing, China. Safety precautions are outlined for handling, storage, exposure control, firefighting, accidental release, and handling of the substance.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...DrDevTaneja1
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
Get Covid Testing at Fit to Fly PCR TestNX Healthcare
A Fit-to-Fly PCR Test is a crucial service for travelers needing to meet the entry requirements of various countries or airlines. This test involves a polymerase chain reaction (PCR) test for COVID-19, which is considered the gold standard for detecting active infections. At our travel clinic in Leeds, we offer fast and reliable Fit to Fly PCR testing, providing you with an official certificate verifying your negative COVID-19 status. Our process is designed for convenience and accuracy, with quick turnaround times to ensure you receive your results and certificate in time for your departure. Trust our professional and experienced medical team to help you travel safely and compliantly, giving you peace of mind for your journey.www.nxhealthcare.co.uk
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
At Malayali Kerala Spa Ajman, Full Service includes individualized care for every client. We specifically design each massage session for the individual needs of the client. Our therapists are always willing to adjust the treatments based on the client's instruction and feedback. This guarantees that every client receives the treatment they expect.
By offering a variety of massage services, our Ajman Spa Massage Center can tackle physical, mental, and emotional illnesses. In addition, efficient identification of specific health conditions and designing treatment plans accordingly can significantly enhance the quality of massaging.
At Malayali Kerala Spa Ajman, we firmly believe that everyone should have the option to experience top-quality massage services regularly. To achieve that goal we offer cheap massage services in Ajman.
If you are interested in experiencing transformative massage treatment at Malayali Kerala Spa Ajman, you can use our Ajman Massage Center WhatsApp Number to schedule your next massage session.
Contact @ +971 529818279
Visit @ https://malayalikeralaspaajman.com/
PrudentRx: A Resource for Patient Education and Engagement
Neo stop 300 hn msds
1. CIPC 300 g/L HN
Safety Data Sheet
according to Regulation (EC) No. 453/2010
Date of issue: 25/07/2006 Revision date: 25/02/2015 Supersedes: 13/06/2014 Version: 10.1
25/02/2015 EN (English) 1/11
SECTION 1: Identification of the substance/mixture and of the company/undertaking
1.1. Product identifier
Product form : Mixture
Trade name : CIPC 300 g/L HN
Product code : CA701406
Synonyms : CIPC 300 g/L HN
1.2. Relevant identified uses of the substance or mixture and uses advised against
1.2.1. Relevant identified uses
Main use category : Professional use
Industrial/Professional use spec : Pesticide
Agriculture.
Use of the substance/mixture : Plant growth regulation.
1.2.2. Uses advised against
No additional information available
1.3. Details of the supplier of the safety data sheet
AGRIPHAR S.A.
Rue de Renory, 26/1
B-4102 Ougrée - Belgium
T +32 (0)4 385 97 11 - F +32 (0)4 385 97 49
info@agriphar.com - http://www.agriphar.com
1.4. Emergency telephone number
Emergency number : +32 (0)4 385 97 11 (8h - 16h35)
112 (European Emergency Number)
Country Organisation/Company Address Emergency number
AUSTRIA Vergiftungsinformationszentrale (Poisons
Information Centre)
Allgemeines Krankenhaus Waehringer
Geurtel 18-20
1090 Wien
+43 1 406 43 43
BELGIUM Centre Anti-Poisons/Antigifcentrum
c/o Hôpital Central de la Base - Reine Astrid
Rue Bruyn
B -1120 Brussels
+32 70 245 245
BULGARIA National Toxicological Information Centre
National Clinical Toxicology Centre, Emergency Medical Institute
"Pirogov"
21 Totleben Boulevard
1606 SOFIA
+359 2 9154 409
CROATIA Poisons Control Centre
Institute of Medical Research & Occupational Health
Ksaverska Cesta 2
P.O. Box 291
HR-10000 Zagreb
+385 1 234 8342
DENMARK Poison Information Centre
Bispebjerg Hospital
Bispebjerg Bakke 23, 60, 1
DK-2400 Copenhagen NV
+45 82 12 12 12
+45 35 31 55 55
ESTONIA Estonian Poison Information Centre Gonsiori 29
15027 Tallinn
16662
FRANCE ORFILA + 33 (0)1 45 42 59 59
FRANCE INRS 65 boulevard Richard-Lenoir
75011 Paris
01 40 44 30 00
FRANCE Centre Antipoison et de Toxicovigilance de Paris
Hôpital Fernand Widal
200 rue du Faubourg Saint-Denis
75475 Paris Cedex 10
+33 1 40 05 48 48
GERMANY Giftberatung Virchow-Klinikum, Medizinische
Fakultät der Humboldt - Universitat zu Berlin
Abt. Innere Medizin mit Schwerpunkt Nephrologie und
Intensivmedizin
Augustenberger Platz 1
13353 Berlin
GERMANY Berliner Betrieb für Zentrale Gesundheitliche
Aufgaben
Institut für Toxikologie, Klinische Toxikologie und Giftnotruf Berlin
Oranienburger Strasse 285
13437 Berlin
+49 30 19240
GERMANY Gemeinsames Giftinformationzentrum der
Länder Mecklenburg-Vorpommern, Sachsen-
Anhalt und Thüringen,
c/o HELIOS Klinikum Erfurt Nordhäuser
Strasse 74
d-99089 Erfurt
+49 361 730 730
GERMANY Vergiftungs-Informations-Zentrale
Zentrum fur Kinderheilkunde und Jugendmedizin
Mathildenstrasse 1
D-79106 Freiburg
+49 761 19240
GERMANY Giftinformationszentrum-Nord
Zentrum Pharmakologie und Toxikologie der Universität
Gottingen
Robert-Koch Strasse 40
D-37075 Gottingen
: +49 551 19240
GERMANY Informations und Beratungszentrum für
Vergiftungsfälle
Klinik für Kinder und Jugendmedizin des Universitätsklinikums
des Saarlandes, Universitätsklinikum des Saarlandes
Kirrberger Straße, Gebäude 9
D-66421 Homburg/Saar
+49 6841 19240
2. CIPC 300 g/L HN
Safety Data Sheet
according to Regulation (EC) No. 453/2010
25/02/2015 EN (English) 2/11
Country Organisation/Company Address Emergency number
GERMANY Beratungstelle bei Vergiftungen, Klinische
Toxikologie und Beratungsstelle bei
Vergiftungen
der Länder Rheinland-Pfalz und Hessen, Universitätsklinikum
Langenbeckstrasse 1
55131 Mainz
+49 6131 19240
GERMANY Toxikologische Abteilung der II Medizinische
Klinik und Poliklinik
rechts der Isar der Technischen Universität
Ismaninger Strasse 22
81675 Munich
+49 89 19240
GERMANY Nurenberg Nürnberg
Giftnotruf Nürnberg, Medizinische Klinik 2, Klinikum Nürnberg,
Lehrstuhl Innere Medizin-Gerontologie, Universität-Nürnberg
Professor-Ernst-Nathan-Strasse 1
90419 Nurenberg
: +49 911 3892665
GREECE Poisons Information Centre
Children's Hospital "Aglaia. Kyriakou"
11527 Athens +30 210 779 3777
GREECE Poisons Information Centre
Children's Hospital "Aglaia. Kyriakou"
11527 Athens +30 210 779 3777
IRELAND (REPUBLIC
OF)
National Poisons Information Centre
Beaumont Hospital
Beaumont Hospital Beaumont Road
9 Dublin
+353 1 809 2166
(public)/+353 1 837 9964
(medical professionals)
+44 (0)870 190 6777
ITALY Centro Antiveleni (Poisons Centre)
Dipartimento di Tossicologia Clinica, Universita Cattolica del
Sacro Cuore
Largo Agostino Gemelli 8
I-00168 Roma
+39 06 305 4343
MADAGASCAR Service de Reanimation Medicale et de
Toxicologie Clinique, Hôpital Ravoahangy
Antananarivo +261 20 225510
Magyarország Országos Kémiai Biztonsági Intézet
Egészségügyi Toxikológiai Tájékoztató Szolgálat
Nagyvárad tér 2.
Postacím: 1437 Budapest, Pf. 839
1097 Budapest
+36 80 20 11 99
Mexico Centro Regional de Informaciòn y Atenciòn
Toxicològica
Av. los Angeles Esquina Analco
Unidad Administrativa Reforma
Ciudad de Guadalajara, Jalisco
+52 3336 50 30 60
Mexico Servicio de Toxicologia Clinica Hospital Juarez
Mexico
Avda. Instit uto Politecnico Nacional,
5160
Colonia Magdalena de las Salinas.
Del.G.A. Madero
+52 44 55 399 36665
Mexico Centro Regional de Informacion y Atencion
Toxicologica
Los Angeles y Analco
Guadalajara, Jalisco
+52 33 36 69 13 38
Mexico Centro de Información y Asistencia Toxicológica
Hospital de Pediatría Centro Médico Nacional
Siglo XXI. IMSS
Avenida Cuauhtémoc 330 Col. Doctores
Delegación Cuauhtémoc
México, D.F.
+52 27 69 00 extn 22317
Mexico Servicio de Informacion Toxicologica Sintox Tintoreto #32 Edif. a Desp. Col.
Nochebuena Mixcoac
México, D.F.
1 800 009 2800
Mexico Centro de Informacion y Asistencia Toxicologica
Centro Medico Nacional La Raza
Jacarandas y Vallejo s-n Col La Raza
Delegación Azcapotzalco
México, D.F.
+52 44 55 39 397 381
Mexico Centro de Información y Asistencia Toxicológica Av. Instituto Politécnico Nacional No.
5160
Col. Magdalena de las Salinas. México
D.F. Delegación Gustavo A. Madero
07760 México, D.F.
+55 399 36665
Mexico Centro de Información Toxicologica Michoacán Av. Madero Ote No. 686, Centro
Morelia, Michoacán
+52 443 3 17 51 63
Mexico Centro Estatal de Información Toxicológica Arieta No. 707
Colonia La Surtidora
Pachuca, Hidalgo
1 800 557 83 88
Mexico Centro de Información Toxicológica de Veracruz
- CITVER
Av. 20 de Noviembre 1074
Col. Centro
Veracruz
+52 229 9329753
NETHERLANDS National Poisons Information Centre
National Institute for Public Health and the Environment, NB this
service is only available to health professionals
P.O. Box 1
3720 BA Bilthoven
+31 30 274 88 88
ROMANIA TOXAPEL
Emergency Clinical Hospital for Children "Grigore Alexandrescu"
Boulevardul Iancu de Hunedoara 30-32
Bucharest
+40 2121 06282
+40 2121 06183
ROMANIA Department of Clinical Toxicology
Spitalul de Urgenta Floreasca
Calea Floreasca
Bucharest
+40 21 230 8000
Serbia National Poison Control Centre
Military Medical Academy, Vonomedicinska Akademija
Crnotravska 17
Belgrade
+381 11 3608 440
SPAIN Unitat de Toxicologia Clinica
Servicio de Urgencias
Hospital Clinic I Provincial de Barcelona
C/Villarroel, 170
E-08036 Barcelona
+34 93 227 98 33
+34 93 227 54 00 bleep 190
SPAIN Instituto de Toxicologia C/Merced 1
8002 Barcelona
+34 93 317 44 00
SPAIN Servicio de Información Toxicológica
Instituto Nacional de Toxicología, Departamento de Madrid
Calle Luis Cabrera 9
E-28002 Madrid
+34 91 562 04 20
SPAIN Servicio de Información Toxicológica
Instituto Nacional de Toxicología, Departamento de Sevilla
Carretera de San Jerónimo Km 0,4
E-41080 Sevilla
+34 95 437 12 33
SWEDEN Giftinformationscentralen
Swedish Poisons Information Centre, Karolinska Hospital
Box 60 500
SE-171 76 Stockholm
+46 8 33 12 31
(International) 112 (National)
SWITZERLAND Centre Suisse d'Information Toxicologique
Swiss Toxicological Information Centre
Freiestrasse 16
Postfach CH-8028 Zürich
145
+41 44 251 51 51
3. CIPC 300 g/L HN
Safety Data Sheet
according to Regulation (EC) No. 453/2010
25/02/2015 EN (English) 3/11
Country Organisation/Company Address Emergency number
Worldwide WHO http://www.who.int/gho/phe/chemical_saf
ety/poisons_centres/en/
SECTION 2: Hazards identification
2.1. Classification of the substance or mixture
Classification according to Regulation (EC) No. 1272/2008 [CLP]Show CLP information + DPD classification in section 2.1
Eye Irrit. 2 H319
Skin Sens. 1 H317
Carc. 2 H351
STOT SE 3 H335
STOT SE 3 H336
STOT RE 2 H373
Aquatic Chronic 2 H411
Full text of H-phrases: see section 16
Classification according to Directive 67/548/EEC [DSD] or 1999/45/EC [DPD]
Carc.Cat.3; R40
Xn; R48/22
Xi; R36/37/38
N; R51/53
R67
R43
Full text of R-phrases: see section 16
Adverse physicochemical, human health and environmental effects
No additional information available
2.2. Label elements
Labelling according to Regulation (EC) No. 1272/2008 [CLP]
Hazard pictograms (CLP) :
GHS07 GHS08 GHS09
CLP Signal word : Warning
Hazard statements (CLP) : H317 - May cause an allergic skin reaction
H319 - Causes serious eye irritation
H335 - May cause respiratory irritation
H336 - May cause drowsiness or dizziness
H351 - Suspected of causing cancer
H373 - May cause damage to organs through prolonged or repeated exposure
H411 - Toxic to aquatic life with long lasting effects
Precautionary statements (CLP) : P201 - Obtain special instructions before use
P260 - Do not breathe vapours
P280 - Wear eye protection, protective clothing, protective gloves
P302+P352 - IF ON SKIN: Wash with plenty of soap and water
P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing
P308+P313 - IF exposed or concerned: Get medical advice/attention
P312 - Call a POISON CENTER or doctor/physician if you feel unwell
P333+P313 - If skin irritation or rash occurs: Get medical advice/attention
P337+P313 - If eye irritation persists: Get medical advice/attention
P501 - Dispose of contents/container to an authorised waste collection point
EUH phrases : EUH401 - To avoid risks to human health and the environment, comply with the instructions for
use
2.3. Other hazards
No additional information available
SECTION 3: Composition/information on ingredients
3.1. Substance
Not applicable
4. CIPC 300 g/L HN
Safety Data Sheet
according to Regulation (EC) No. 453/2010
25/02/2015 EN (English) 4/11
3.2. Mixture
Name Product identifier % Classification according to
Directive 67/548/EEC
Solvent >= 70 Carc.Cat.3; R40
Xi; R36/37/38
R67
CIPC (CAS No) 101-21-3
(EC no) 202-925-7
(EC index no) 006-096-00-0
22,3 - 24,1 Carc.Cat.3; R40
Xn; R48/22
N; R51/53
Name Product identifier % Classification according to
Regulation (EC) No.
1272/2008 [CLP]
Solvent >= 70 Skin Irrit. 2, H315
Eye Irrit. 2, H319
Carc. 2, H351
STOT SE 3, H336
STOT SE 3, H335
STOT RE 2, H373
CIPC (CAS No) 101-21-3
(EC no) 202-925-7
(EC index no) 006-096-00-0
22,3 - 24,1 Carc. 2, H351
STOT RE 2, H373
Aquatic Acute 1, H400
Aquatic Chronic 2, H411
Full text of R- and H-phrases: see section 16
SECTION 4: First aid measures
4.1. Description of first aid measures
First-aid measures general : If medical advice is needed, have product container or label at hand.
First-aid measures after inhalation : IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for
breathing. In case of breathing difficulties administer oxygen. In case of irregular breathing or
respiratory arrest provide artificial respiration. In all cases of doubt, or when symptoms persist,
seek medical advice.
First-aid measures after skin contact : After contact with skin, take off immediately all contaminated clothing, and wash immediately
with plenty of water and soap. If skin irritation occurs: Get medical advice/attention.
First-aid measures after eye contact : Rinse immediately carefully and thoroughly with eye-bath or water. Remove contact lenses, if
present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention.
First-aid measures after ingestion : If swallowed, rinse mouth with water (only if the person is conscious). Do not induce vomiting.
Immediately get medical attention.
4.2. Most important symptoms and effects, both acute and delayed
Symptoms/injuries after inhalation : Sore throat. Cough. Dizziness. Headache. drowsiness. Nausea. Weakness. Unconsciousness.
Symptoms/injuries after skin contact : Redness. Tingling/irritation of the skin.
Symptoms/injuries after eye contact : Redness, pain. Direct contact may result in corneal injury.
Symptoms/injuries after ingestion : Abdominal pain, nausea. Burning sensation. See inhalation.
Chronic symptoms : Repeated or prolonged skin contact may cause dermatitis and defatting. May cause damage to
organs through prolonged or repeated exposure.
4.3. Indication of any immediate medical attention and special treatment needed
Treat symptomatically.
SECTION 5: Firefighting measures
5.1. Extinguishing media
Suitable extinguishing media : Foam. Dry extinguishing powder. Carbon dioxide (CO2). Water fog.
Unsuitable extinguishing media : High power water jet.
5.2. Special hazards arising from the substance or mixture
Fire hazard : Non-flammable.
5.3. Advice for firefighters
Precautionary measures fire : No open flames. No smoking.
Firefighting instructions : Evacuate and limit access. Use water spray jet to protect personnel and to cool endangered
containers.
Protection during firefighting : Wear full chemical protective clothing. If technical exhaust or ventilation measures are not
possible or insufficient, respiratory protection must be worn.
Other information : Collect contaminated fire extinguishing water separately. Do not allow entering drains or
surface water.
5. CIPC 300 g/L HN
Safety Data Sheet
according to Regulation (EC) No. 453/2010
25/02/2015 EN (English) 5/11
SECTION 6: Accidental release measures
6.1. Personal precautions, protective equipment and emergency procedures
General measures : When leaks or spills occur, only properly protected personnel should remain in the area.
6.1.1. For non-emergency personnel
Protective equipment : Wear suitable protective clothing, gloves and eye or face protection. In case of insufficient
ventilation, wear suitable respiratory equipment.
Emergency procedures : Evacuate area. Provide adequate ventilation to minimize dust and/or vapour concentrations.
Call in an expert. Eliminate every possible source of ignition.
6.1.2. For emergency responders
Protective equipment : Wear a self-contained breathing apparatus and chemical protective clothing.
6.2. Environmental precautions
Do not empty into drains, dispose of this material and its container at hazardous or special waste collection point. Notify authorities if product enters
sewers or public waters.
6.3. Methods and material for containment and cleaning up
For containment : Prevent spreading in sewers. Impound and recover large spill by mixing it with inert granular
solids.
Methods for cleaning up : Collect spills and put it into appropriated container.
Other information : Special danger of slipping by leaking/spilling product.
6.4. Reference to other sections
Exposure controls/personal protection. Disposal considerations.
SECTION 7: Handling and storage
7.1. Precautions for safe handling
Precautions for safe handling : Handle in accordance with good industrial hygiene and safety procedures. Keep away from
heat/sparks/open flames/hot surfaces. - No smoking. Do not allow to enter into surface water or
drains.
Handling temperature : at room temperature
Hygiene measures : Do no eat, drink or smoke when using this product. Take off contaminated clothing and wash
before reuse. Wash hands and other exposed areas with mild soap and water before eating,
drinking or smoking and when leaving work.
7.2. Conditions for safe storage, including any incompatibilities
Technical measures : Ground well. Use explosion-proof machinery, apparatus, ventilation facilities, tools etc.
Storage conditions : Protect against direct sunlight.
Incompatible products : Strong acid. Strong bases. Oxidizing agents, strong.
Maximum storage period : 2 year(s)
Storage temperature : Protect from freezing
Storage area : Keep container tightly closed in a cool, well-ventilated place. Provide for retaining containers,
eg. floor pan without outflow.
Packaging materials : Keep only in the original container. Keep locked up.
7.3. Specific end use(s)
No additional information available
SECTION 8: Exposure controls/personal protection
8.1. Control parameters
Solvent
Austria MAK (mg/m³) 175 mg/m³
Austria MAK (ppm) 50 ppm
Belgium Limit value (mg/m³) 180 mg/m³
Belgium Limit value (ppm) 50 ppm (2011)
Belgium Short time value (mg/m³) 350 mg/m³
Belgium Short time value (ppm) 100 ppm
France VME (mg/m³) 180 mg/m³
France VME (ppm) 50 ppm
France VLE (mg/m³) 350 mg/m³
France VLE (ppm) 100 ppm
Germany TRGS 900 Occupational exposure limit value (mg/m³) 260 mg/m³
Germany TRGS 900 Occupational exposure limit value (ppm) 75 ppm
United Kingdom WEL TWA (mg/m³) 350 mg/m³
6. CIPC 300 g/L HN
Safety Data Sheet
according to Regulation (EC) No. 453/2010
25/02/2015 EN (English) 6/11
Solvent
United Kingdom WEL TWA (ppm) 100 ppm
United Kingdom WEL STEL (mg/m³) 1060 mg/m³
United Kingdom WEL STEL (ppm) 300 ppm
Switzerland VME (mg/m³) 180 mg/m³
Switzerland VME (ppm) 50 ppm
Switzerland Remark (CH) RSB:B C3
USA - ACGIH ACGIH STEL (mg/m³) 174 mg/m³
USA - ACGIH ACGIH STEL (ppm) 50 ppm
8.2. Exposure controls
Personal protective equipment : Gloves. Gas mask. Safety glasses.
Hand protection : Wear suitable gloves resistant to chemical penetration. NBR (Nitrile rubber). For special
purposes, it is recommended to check the resistance to chemicals of the protective gloves
mentioned above together with the supplier of these gloves.
Eye protection : Face shield. Chemical goggles or safety glasses
Skin and body protection : Skin protection appropriate to the conditions of use should be provided
Respiratory protection : If technical exhaust or ventilation measures are not possible or insufficient, respiratory
protection must be worn.
Environmental exposure controls : Notify authorities if product enters sewers or public waters.
Other information : Emergency eye wash fountains and safety showers should be available in the immediate
vicinity of any potential exposure.
SECTION 9: Physical and chemical properties
9.1. Information on basic physical and chemical properties
Physical state : Liquid
Appearance : clear.
Colour : yellow.
Odour : characteristic.
Odour threshold : No data available
pH : 5,82 - 7,09
Relative evaporation rate (butylacetate=1) : No data available
Melting point : No data available
Freezing point : No data available
Boiling point : 45 °C
Flash point : No flash point - measurement carried out until boiling temperature.
Auto-ignition temperature : > 650 °C
Decomposition temperature : No data available
Flammability (solid, gas) : No data available
Vapour pressure : No data available
Relative vapour density at 20 °C : No data available
Relative density : No data available
Density : 1,28 g/cm³ (20°C +/- 0.5°C)
Solubility : No data available
Log Pow : No data available
Viscosity, kinematic : No data available
Viscosity, dynamic : < 6,05 mPa.s (20°C)
Explosive properties : The study does not need to be conducted because there are no chemical groups associated
with explosive properties present in the molecule.
Oxidising properties : not oxidizing.
Explosive limits : No data available
7. CIPC 300 g/L HN
Safety Data Sheet
according to Regulation (EC) No. 453/2010
25/02/2015 EN (English) 7/11
9.2. Other information
No additional information available
SECTION 10: Stability and reactivity
10.1. Reactivity
When exposed to heat, may decompose liberating hazardous gases.
10.2. Chemical stability
Stable under normal conditions.
10.3. Possibility of hazardous reactions
None under normal conditions. Refer to section 10.1 on Reactivity.
10.4. Conditions to avoid
Protect against direct sunlight. Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
10.5. Incompatible materials
Strong acid. Strong bases. Strong oxidizing agents.
10.6. Hazardous decomposition products
When heated to decomposition, emits dangerous fumes. Carbon dioxide (CO2). Carbon monoxide. Nitrogen oxides (NOx).
SECTION 11: Toxicological information
11.1. Information on toxicological effects
Acute toxicity : Not classified
CIPC 300 g/L HN
LD50 oral rat > 2000 mg/kg
LD50 dermal rat > 4000 mg/kg
LC50 inhalation rat (mg/l) > 6,73 mg/l/4h
CIPC (101-21-3)
LD50 oral rat 4200 mg/kg
LD50 dermal rat > 2000 mg/kg
Solvent
LD50 oral rat > 2000 mg/kg
LD50 dermal rat > 2000 mg/kg
LC50 inhalation rat (mg/l) 88 mg/l
Skin corrosion/irritation : Not classified.
OECD 404 - EC n° 440/2008 B.4
pH: 5,82 - 7,09
Serious eye damage/irritation : Causes serious eye irritation.
OECD 405 - EC n° 440/2008 B.5
pH: 5,82 - 7,09
Respiratory or skin sensitisation : May cause an allergic skin reaction.
OECD 406 - EC n° 440/2008 B.6 (Albino Guinea Pig)
Germ cell mutagenicity : Not classified
Carcinogenicity : Suspected of causing cancer.
Reproductive toxicity : Not classified
Specific target organ toxicity (single exposure) : May cause respiratory irritation. May cause drowsiness or dizziness.
Specific target organ toxicity (repeated
exposure)
: May cause damage to organs through prolonged or repeated exposure.
Aspiration hazard : Not classified
CIPC 300 g/L HN
Viscosity, kinematic 4,72656250 mm²/s
SECTION 12: Ecological information
12.1. Toxicity
CIPC 300 g/L HN
LC50 fish 1 12 mg/l (96h Salmo gairdneri)
EC50 Daphnia 1 1,98 mg/l (48h Daphnia magna)
ErC50 (algae) 2,94 mg/l (72h Selenastrum capricornutum)
8. CIPC 300 g/L HN
Safety Data Sheet
according to Regulation (EC) No. 453/2010
25/02/2015 EN (English) 8/11
CIPC (101-21-3)
LC50 fish 1 7,5 mg/l (96h Salmo gairdneri)
EC50 Daphnia 1 4 mg/l (48h Daphnia magna)
LC50 fish 2 5,3 mg/l (96h Cyprinus carpio)
ErC50 (algae) 1 mg/l (96h Navicula pelliculosa)
ErC50 (other aquatic plants) 1,67 mg/l (7d; Lemna minor)
NOEC chronic fish 0,32 mg/l (34d Brachydanio rerio)
NOEC chronic crustacea 1 mg/l (21d Daphnia magna)
Solvent
LC50 fish 1 193 mg/l (96h)
EC50 Daphnia 1 480 mg/l (48h Daphnia magna)
ErC50 (algae) > 662 mg/l (96h)
12.2. Persistence and degradability
Solvent
Persistence and degradability Not readily biodegradable.
12.3. Bioaccumulative potential
CIPC (101-21-3)
BCF fish 1 144
Log Pow 3,76 (20°C; pH=7)
Solvent
Log Pow 1,25
Bioaccumulative potential There is no bioaccumulation.
12.4. Mobility in soil
CIPC 300 g/L HN
Surface tension 29,6 mN/m (25°C)
Solvent
Surface tension 28,1 mN/m (20°C)
12.5. Results of PBT and vPvB assessment
No additional information available
12.6. Other adverse effects
No additional information available
SECTION 13: Disposal considerations
13.1. Waste treatment methods
Regional legislation (waste) : Disposal must be done according to official regulations.
Waste treatment methods : Dispose of this material and its container to hazardous or special waste collection point.
Additional information : Do not contaminate water with the product or its container (Do not clean application equipment
near surface water/Avoid contamination via drains from farmyards and roads). Notify authorities
if product enters sewers or public waters.
SECTION 14: Transport information
In accordance with ADR / RID / IMDG / IATA / ADN
ADR IMDG IATA ADN RID
14.1. UN number
2902 2902 2902 2902 2902
14.2. UN proper shipping name
PESTICIDE, LIQUID,
TOXIC, N.O.S.
PESTICIDE, LIQUID,
TOXIC, N.O.S.
Pesticide, liquid, toxic,
n.o.s.
PESTICIDE, LIQUID,
TOXIC, N.O.S.
PESTICIDE, LIQUID,
TOXIC, N.O.S.
Transport document description
UN 2902 PESTICIDE,
LIQUID, TOXIC, N.O.S.
(CIPC, solvent), 6.1, III, (E),
ENVIRONMENTALLY
HAZARDOUS
UN 2902 PESTICIDE,
LIQUID, TOXIC, N.O.S.
(CIPC, solvent), 6.1, III,
MARINE
POLLUTANT/ENVIRO
NMENTALLY
HAZARDOUS
9. CIPC 300 g/L HN
Safety Data Sheet
according to Regulation (EC) No. 453/2010
25/02/2015 EN (English) 9/11
ADR IMDG IATA ADN RID
14.3. Transport hazard class(es)
6.1 6.1 6.1 6.1 6.1
14.4. Packing group
III III III III III
14.5. Environmental hazards
Dangerous for the
environment : Yes
Dangerous for the
environment : Yes
Marine pollutant : Yes
Dangerous for the
environment : Yes
Dangerous for the
environment : Yes
Dangerous for the
environment : Yes
14.6. Special precautions for user
14.6.1. Overland transport
Classification code (ADR) : T6
Special provisions (ADR) : 61, 274, 648
Limited quantities (ADR) : 5l
Excepted quantities (ADR) : E1
Packing instructions (ADR) : P001, IBC03, LP01, R001
Mixed packing provisions (ADR) : MP19
Portable tank and bulk container instructions
(ADR)
: T7
Portable tank and bulk container special
provisions (ADR)
: TP2, TP28
Tank code (ADR) : L4BH
Tank special provisions (ADR) : TU15, TE19
Vehicle for tank carriage : AT
Transport category (ADR) : 2
Special provisions for carriage - Packages
(ADR)
: V12
Special provisions for carriage - Loading,
unloading and handling (ADR)
: CV13, CV28
Special provisions for carriage - Operation
(ADR)
: S9
Hazard identification number (Kemler No.) : 60
Orange plates :
Tunnel restriction code : E
EAC code : 2X
APP code : B
14.6.2. Transport by sea
Special provisions (IMDG) : 61, 223, 274
Limited quantities (IMDG) : 5 L
Excepted quantities (IMDG) : E1
Packing instructions (IMDG) : P001, LP01
IBC packing instructions (IMDG) : IBC03
Tank instructions (IMDG) : T7
Tank special provisions (IMDG) : TP2, TP28
EmS-No. (Fire) : F-A
EmS-No. (Spillage) : S-A
Stowage category (IMDG) : A
10. CIPC 300 g/L HN
Safety Data Sheet
according to Regulation (EC) No. 453/2010
25/02/2015 EN (English) 10/11
14.6.3. Air transport
PCA Excepted quantities (IATA) : E1
PCA Limited quantities (IATA) : Y642
PCA limited quantity max net quantity (IATA) : 2L
PCA packing instructions (IATA) : 655
PCA max net quantity (IATA) : 60L
CAO packing instructions (IATA) : 663
CAO max net quantity (IATA) : 220L
Special provisions (IATA) : A3, A4
ERG code (IATA) : 6L
14.6.4. Inland waterway transport
Classification code (ADN) : T6
Special provisions (ADN) : 61, 274, 648, 82
Limited quantities (ADN) : 5 L
Excepted quantities (ADN) : E1
Equipment required (ADN) : PP, EP, TOX, A
Ventilation (ADN) : VE02
Number of blue cones/lights (ADN) : 0
Not subject to ADN : No
14.6.5. Rail transport
Classification code (RID) : T6
Special provisions (RID) : 61, 274, 648
Limited quantities (RID) : 5L
Excepted quantities (RID) : E1
Packing instructions (RID) : P001, IBC03, LP01, R001
Mixed packing provisions (RID) : MP19
Portable tank and bulk container instructions
(RID)
: T7
Portable tank and bulk container special
provisions (RID)
: TP2, TP28
Tank codes for RID tanks (RID) : L4BH
Special provisions for RID tanks (RID) : TU15
Transport category (RID) : 2
Special provisions for carriage – Packages
(RID)
: W12
Special provisions for carriage - Loading,
unloading and handling (RID)
: CW13, CW28, CW31
Colis express (express parcels) (RID) : CE8, CE12
Hazard identification number (RID) : 60
Carriage prohibited (RID) : No
14.7. Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable
SECTION 15: Regulatory information
15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture
15.1.1. EU-Regulations
The following restrictions are applicable according to Annex XVII of the REACH Regulation (EC) No 1907/2006:
3. Liquid substances or mixtures which are regarded as dangerous in
accordance with Directive 1999/45/EC or are fulfilling the criteria for any
of the following hazard classes or categories set out in Annex I to
Regulation (EC) No 1272/2008
CIPC 300 g/L HN
59. Dichloromethane Solvent
Contains no substance on the REACH candidate list
Contains no REACH Annex XIV substances
15.1.2. National regulations
Germany
11. CIPC 300 g/L HN
Safety Data Sheet
according to Regulation (EC) No. 453/2010
25/02/2015 EN (English) 11/11
Water hazard class (WGK) : 3 - severe hazard to waters
Storage class (LGK) : LGK 10 - Combustible liquids
15.2. Chemical safety assessment
No additional information available
SECTION 16: Other information
Indication of changes:
UN-No.(ADN) Added
Class (ADN) Added
Supersedes Modified
Revision date Modified
For mixture Modified
2.1 Classification according
to Regulation (EC) No.
1272/2008 [CLP]
Modified
2.2 EUH phrases Added
14.6 Instruction "passenger" -
Limited quantities (ICAO)
Removed
14.6 Instruction "passenger"
(ICAO)
Removed
14.6 Instruction "cargo"
(ICAO)
Removed
14.6 Special provisions (ADR) Modified
Full text of R-, H- and EUH-phrases:
Aquatic Acute 1 Hazardous to the aquatic environment — Acute Hazard, Category 1
Aquatic Chronic 2 Hazardous to the aquatic environment — Chronic Hazard, Category 2
Carc. 2 Carcinogenicity, Category 2
Eye Irrit. 2 Serious eye damage/eye irritation, Category 2
Skin Irrit. 2 Skin corrosion/irritation, Category 2
Skin Sens. 1 Sensitisation — Skin, category 1
STOT RE 2 Specific target organ toxicity — Repeated exposure, Category 2
STOT SE 3 Specific target organ toxicity — Single exposure, Category 3, Respiratory tract irritation
STOT SE 3 Specific target organ toxicity — Single exposure, Category 3, Narcosis
H315 Causes skin irritation
H317 May cause an allergic skin reaction
H319 Causes serious eye irritation
H335 May cause respiratory irritation
H336 May cause drowsiness or dizziness
H351 Suspected of causing cancer
H373 May cause damage to organs through prolonged or repeated exposure
H400 Very toxic to aquatic life
H411 Toxic to aquatic life with long lasting effects
R36/37/38 Irritating to eyes, respiratory system and skin
R40 Limited evidence of a carcinogenic effect
R43 May cause sensitisation by skin contact
R48/22 Harmful: danger of serious damage to health by prolonged exposure if swallowed
R51/53 Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic
environment
R67 Vapours may cause drowsiness and dizziness
N Dangerous for the environment
Xi Irritant
Xn Harmful
SDS EU (REACH Annex II)
This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be
construed as guaranteeing any specific property of the product